Yüklüyor......
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
Immuno-oncology (IO) has been an active area of oncology research. Following US FDA approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA-4 monoclonal antibody), in 2011, and of the first oncolytic virus, Imlygic (talimogene laherparepvec), in 2015, there has be...
Kaydedildi:
| Yayımlandı: | Int J Mol Sci |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7697902/ https://ncbi.nlm.nih.gov/pubmed/33207653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21228627 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|